The aim of present study was to evaluate antiangiogenic activity of newly synthesized caffeic acid
methyl benzoate amide (CAMBA) in EAC-bearing mice. The IC50 value of CAMBA against the Hep-G2
liver carcinoma cell line was calculated. Adult albino mice weighing 25 ± 5 g was used to assess the
antiangiogenic activity of CAMBA (25 and 50 mg/k.b.w.) in EAC-bearing mice. IC50 CAMBA against
the Hep-G2 cell line equals 52.8 μg/mL. The daily oral administration of CAMBA at concentrations
of 25 and 50 mg/kg.b.w. for 30 days to EAC-bearing mice resulted in a significant improvement in
tumor volume and tumor weight, ALT, AST, ALP, MMP-2 and -9, TNF-α, NOx, TBARs, GSH, CAT,
SOD, GPx and VEGF-C gene expression in EAC-bearing mice. Furthermore, CAMBA almost
normalized these effects in liver histoarchitecture. The biochemical, histological and ultrasound
examinations of our study suggested that CAMBA have antiangiogenic activity in EAC-bearing mice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.